… of COVID-19 strongly recommends nirmatrelvir plus ritonavir as an option for patients with
non-severe COVID-19 … the use of nirmatrelvir plus ritonavir for patients with non-severe COVID-…

… good effectivity in preventing the progression of COVID-19 to severe disease state. In this …
of nirmatrelvir and ritonavir in human plasma of patients treated for COVID-19 with Paxlovid…

… Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir (NMV-r)
in high-risk nonhospitalized unvaccinated patients reduced the risk of progression to severe …

… as nirmatrelvir-ritonavir, but for patients with mild COVID-19, nirmatrelvir-ritonavir could …
efficacy of azvudine and nirmatrelvir-ritonavir in treating COVID-19 using a retrospective, …

… of COVID-19 (14). By examining 2 cohorts of hospitalized patients who were prescribed
molnupiravir or nirmatrelvir–ritonavir, … in reducing mortality and severe COVID-19 in the inpatient …

… Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients
with COVID-19, but … Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a …

… for COVID-19 such as Paxlovid. This antiviral drug, a combination of nirmatrelvir and
ritonavir, is orally active and used in treatment and post-exposure prophylaxis of COVID-19. …

… COVID-19 are urgently needed. Here, we report the outcome of patients treated with
nirmatrelvir/ritonavir … (CP) in six immunocompromised patients with non-resolving COVID-19. …

… the metabolism of nirmatrelvir.[4]. The EPIC-HR trial was conducted in the COVID-19 delta
… -risk patients who were treated with either nirmatrelvir/ritonavir or placebo within five days of …

… nirmatrelvir plus ritonavir was assigned randomly among EUA-eligible individuals with early
COVID-19 … Date of COVID-19 diagnosis was used as start of period of risk in both study arms…